Clinical Trials Logo
  1. Home
  2. Chondrosarcoma
  3. NCT00592748

Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine

Chondrosarcoma Clinical Trial

Official title:
Randomized Study of Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine

Clinical Trial Summary

The primary purpose of this study is to determine if the administration of a higher dose would decrease the chance of tumor recurrence, compared to the risk of tumor recurrence with a lower dose. Most of the treatment will be given protons, but participants may receive a small portion of treatment with x-rays, because less radiation is given to the skin with x-rays. This study uses two slightly different doses of radiation It is not clear at this time which of the dose levels is better.

Clinical Trial Description

- Participants will be assigned to a dose level by random chance, like flipping a coin.

- A treatment plan will be determined by a treatment planning CT scan and will either involve 40-44 treatments or 37-40 treatments. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00592748
Study type Interventional
Source Massachusetts General Hospital
Contact
Status Completed
Phase Phase 1/Phase 2
Start date June 1999
Completion date May 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT03955042 - Pemetrexed for the Treatment of Chordoma Phase 1
Completed NCT01347307 - Stereotactic Body Radiotherapy for Spine Tumors N/A
Active, not recruiting NCT00496119 - Proton Beam Therapy for Chordoma Patients Phase 2
Recruiting NCT06029218 - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy N/A
Completed NCT03595228 - BN Brachyury and Radiation in Chordoma Phase 2
Recruiting NCT06140732 - Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma Phase 2
Active, not recruiting NCT01175109 - Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma Phase 1
Completed NCT00150072 - Efficacy and Safety of Imatinib in Chordoma Phase 2
Terminated NCT00003926 - Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Phase 1
Recruiting NCT05041127 - Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma Phase 2
Recruiting NCT05861245 - Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base N/A
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Recruiting NCT03242382 - Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. Phase 2
Completed NCT02520128 - A Study of IMRT in Primary Bone and Soft Tissue Sarcoma N/A
Recruiting NCT01567046 - Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas N/A
Recruiting NCT02986516 - Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease N/A
Completed NCT00919269 - Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Active, not recruiting NCT02989636 - Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma Phase 1
Active, not recruiting NCT03083678 - Afatinib in Locally Advanced and Metastatic Chordoma Phase 2
Completed NCT00713037 - Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas N/A